2017
DOI: 10.22159/ajpcr.2017.v10i8.18869
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Alpha Lipoic Acid in Treatment of Type 2 Diabetes

Abstract: Objective: Antioxidant probably can prevent the progression and complications of Type 2 diabetes mellitus (T2DM). Due to effectiveness of alpha lipoic acid (ALA) as an antioxidant, this study was done in T2DM patients to evaluate the effect of ALA on their diabetic status, lipid profile, and oxidative stress (OS) status.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 35 publications
0
2
0
Order By: Relevance
“…In different clinical trials, α‐LA was used in 100–1,000 mg/day and these studies were placebo‐controlled trials. The doses of 200–300 mg/day showed the best effects on diabetes compared to the placebo control by reducing blood glucose and insulin resistance (Ansar et al, 2011; Jacob, Streeper, et al, 1996; Panda, Panda, & Mishra, 2017; Udupa et al, 2013). According to different studies that were discussed above it seems that α‐LA has a significant effect on the management of hyperglycemia.…”
Section: Clinical Trial Studiesmentioning
confidence: 99%
See 1 more Smart Citation
“…In different clinical trials, α‐LA was used in 100–1,000 mg/day and these studies were placebo‐controlled trials. The doses of 200–300 mg/day showed the best effects on diabetes compared to the placebo control by reducing blood glucose and insulin resistance (Ansar et al, 2011; Jacob, Streeper, et al, 1996; Panda, Panda, & Mishra, 2017; Udupa et al, 2013). According to different studies that were discussed above it seems that α‐LA has a significant effect on the management of hyperglycemia.…”
Section: Clinical Trial Studiesmentioning
confidence: 99%
“…In various dyslipidemia animal models as lipid profile impairment, the α‐LA treatment improved triglyceride levels (Jamor et al, 2018; Mythili et al, 2006; Panda et al, 2017; Pradhan et al, 2014), decreased LDL (Amom et al, 2008; Lukaszuk et al, 2009), increased HDL (Amudha et al, 2007; Carrier et al, 2014; Rideout et al, 2016; Thirunavukkarasu et al, 2004b; Uchendu et al, 2018), and reduced the total plasma cholesterol and free fatty acid (Jacob, Streeper, et al, 1996; E. Kim, Park, Choi, Kim, & Cho, 2008; Okanovic et al, 2015; Ozdogan et al, 2012).…”
Section: In Vivo Studiesmentioning
confidence: 99%